Myovant strengthens executive team

"I am very pleased with the caliber of our new corporate leaders and look forward to working closely with them," said Lynn Seely, President & CEO of Myovant Sciences. Ferreira will be the new Chief Medical Director at Myovant, a biopharmaceutical company focused on the treatment of women specific and endocrine diseases. He was previously the Senior Vice President of the Japanese pharmaceutical company Shionogi Inc., where he was responsible for the clinical development program in the US. Prior to that, he was responsible for the clinical development of women’s health care products at Merck & Co. Ferreira earned his Master’s degree and completed his postgraduate specialist training in obstetrics and gynaecology at Colegio Mayor del Rosario in Bogota, Colombia.

Furthermore, Matthew Langhas has joined the company as General Counsel and Corporate Secretary, Teresa Perney will be the Senior Vice President of Regulatory Affairs and Quality Assurance, and Andria Langenberg is now the Head of Drug Safety and Pharmacovigilance.